Redefining Cancer Drug Development: The Need for a New Roadmap from Discovery to Drug
Interview with Dr. William Hait
Current estimates indicate that the pipeline from concept to cancer drug is a decade-long process that can cost over €2 billion. The realisation that this classical model for cancer drug discovery and development may no longer be effective in the current era of targeted therapy has prompted a re-evaluation of how best to reposition the strategy to deliver innovative new drugs for the cancer patient. Accompanying the European Perspectives article “Redefining Cancer Drug Development: The Need For A New Roadmap From Discovery To Drug”, Dr William Hait, Global Head Janssen Research and Development, shares his vision on the need for approaches that empower functional partnerships between academia and industry to deliver transformational advances for cancer patients. This new approach requires a clear understanding of the medical need, coupled with the most compelling science to deliver meaningful innovations to patients in a rapid fashion.